摘要
目的 探讨冠脉介入前后水化处理在预防造影剂肾病中的价值，为临床造影剂肾病的预防提供参考。方法 选取2020年1月至2021年12月在大竹县人民医院心血管内科进行冠脉介入治疗的80例患者为研究对象，随机将其分为研究组(n=40)和对照组(n=40)，对照组采取常规护理模式，研究组加以水化处理，对比两组患者的护理疗效。结果 护理干预后，研究组患者造影剂肾病发病率明显低于对照组（P<0.05）；护理后，研究组患者的SCr、BUN、Cys-C水平明显低于对照组（P<0.05）；护理后，与对照组相比，研究组患者的UW-QOL生存质量评分明显偏高（P<0.05）；与对照组相比，研究组患者的护理总满意率明显偏高（P<0.05）。结论 冠脉介入前后水化处理能够有效预防造影剂肾病，改善患者的肾功能，提高患者的生存质量和护理满意度，可以在临床上广泛推广和应用。
关键词： 冠脉介入；水化处理；造影剂肾病；生存质量；满意度
Abstract
Objective To investigate the value of hydration before and after coronary intervention in the prevention of contrast nephropathy, and to provide reference for the prevention of clinical contrast nephropathy. Methods A total of 80 patients who underwent coronary intervention in the Department of Cardiovascular Medicine, Dazhu County People's Hospital from January 2020 to December 2021 were selected as the research objects, and they were randomly divided into the study group (n=40) and the control group (n=40). 40), the control group was treated with routine nursing mode, and the research group was treated with hydration, and the nursing efficacy of the two groups of patients was compared. Results After nursing intervention, the incidence of contrast agent nephropathy in the study group was significantly lower than that in the control group (P<0.05); after nursing, the levels of SCr, BUN and Cys-C in the study group were significantly lower than those in the control group (P<0.05); After nursing, compared with the control group, the UW-QOL quality of life score of the patients in the study group was significantly higher (P<0.05); compared with the control group, the total nursing satisfaction rate of the patients in the study group was significantly higher (P<0.05) . Conclusion Hydration treatment before and after coronary intervention can effectively prevent contrast agent nephropathy, improve the renal function of patients, improve the quality of life and nursing satisfaction of patients, and can be widely promoted and applied in clinical practice.
Key words： Coronary intervention; Hydration treatment; Contrast nephropathy; Quality of life; Satisfaction
参考文献 References
[1] 杨波, 邓云超, 谭利国,等. 经皮冠状动脉介入再通对冠状动脉慢性完全闭塞性病变患者左室心肌重塑的影响[J]. 中国循证心血管医学杂志, 2018, 10(4):5.
[2] 李盈, 韦彬, 李珍珍. "双心"护理干预对行经皮冠状动脉介入治疗的冠心病合并焦虑/抑郁患者的影响研究[J]. 实用心脑肺血管病杂志, 2018, 26(5):4.
[3] 郭文飞, 胡允兆, 卢剑华,等. 早期家庭运动心脏康复对急性心肌梗死经皮冠状动脉介入治疗术后患者心室功能的影响[J]. 广东医学, 2018, 39(13):6.
[4] 陆明, 胡鹏飞, 林冬铭,等. 消瘀泄浊饮内服联合水化疗法预防经皮冠状动脉介入术后造影剂肾病的临床研究[J]. 中华中医药杂志, 2019(4):3.
[5] 陈晓扬, 张曦元, 姚姗姗,等. 不同剂量二甲双胍对行直接经皮冠状动脉介入治疗患者造影剂肾病发病率的影响[J]. 实用医学杂志, 2020, 36(20):4.
[6] 徐卓文, 陈新军, 杨增芯,等. 水化联合远程缺血预处理对于老年患者经皮冠状动脉介入术后对比剂肾病的预防[J]. 中国心血管病研究, 2021, 19(11):4.
[7] 程仁力, 尚亚东, 孙彤,等. 强化他汀药物预防经皮冠状动脉介入术后造影剂肾病发生的临床观察[J]. 中国临床保健杂志, 2018, 21(4):4.
[8] Fu N , Yang S , Zhang J , et al. The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study[J]. International Urology & Nephrology, 2018.
[9] 曹金龙, 马鸿兰, 辛宏,等. 沙库巴曲缬沙坦钠片对择期经皮冠状动脉介入治疗的慢性心力衰竭患者造影剂肾病的影响[J]. 世界临床药物, 2021, 42(6):5.
[10] 朱佳璐, 高传玉, 王宪沛,等. 急性冠状动脉综合征合并心力衰竭患者的肾功能状况及冠状动脉介入治疗术后对比剂肾病的发生情况分析[J]. 中国循环杂志, 2019, 34(4):6.
[11] 林丽霞, 申铁梅, 黄嘉熙,等. 强化口服水化预防急性心肌梗死患者急诊经皮冠状动脉介入治疗后发生造影剂肾病的作用[J]. 岭南心血管病杂志, 2019, 25(2):4.
[12] 马光, 王国良, 张韩,等. 左卡尼汀联合水化对伴有肾功能不全的冠心病患者造影剂肾病的预防作用研究[J]. 中国循证心血管医学杂志, 2021, 13(2):3.